Accelerate Diagnostics (NASDAQ:AXDX) Given Outperform Rating at William Blair

Accelerate Diagnostics (NASDAQ:AXDXGet Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a research report issued on Tuesday, RTT News reports.

AXDX has been the subject of a number of other reports. Craig Hallum reduced their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a research report on Monday. StockNews.com started coverage on shares of Accelerate Diagnostics in a research note on Wednesday, March 27th. They issued a “hold” rating for the company.

Check Out Our Latest Stock Analysis on AXDX

Accelerate Diagnostics Trading Up 5.7 %

Shares of AXDX traded up $0.05 during mid-day trading on Tuesday, hitting $0.94. 156,220 shares of the company’s stock were exchanged, compared to its average volume of 129,881. The firm has a market capitalization of $13.70 million, a P/E ratio of -0.19 and a beta of 0.52. Accelerate Diagnostics has a fifty-two week low of $0.83 and a fifty-two week high of $11.90. The business’s 50 day moving average is $1.10 and its two-hundred day moving average is $3.60.

Hedge Funds Weigh In On Accelerate Diagnostics

A number of hedge funds have recently made changes to their positions in AXDX. Sonora Investment Management Group LLC acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at $63,000. Tejara Capital Ltd acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at $78,000. Bank of Montreal Can acquired a new position in shares of Accelerate Diagnostics during the 1st quarter valued at $27,000. Cubist Systematic Strategies LLC acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at $29,000. Finally, Virtu Financial LLC lifted its holdings in shares of Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 17,461 shares in the last quarter. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Articles

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.